


For first-line therapy in mild-to-moderate hypertension

**Discover the classic benefits of a beta-blocker and a diuretic...now at low doses for a side-effect profile comparable to placebo<sup>1\*</sup>**



**ZIAC controls mild-to-moderate hypertension in up to 80% of patients<sup>††</sup>**

**ZIAC controls blood pressure for a full 24 hours for true once-a-day dosing<sup>2</sup>**

**ZIAC minimizes traditional beta-blocker- and HCTZ-associated metabolic effects (hypokalemia, hyperuricemia, hypercholesterolemia, hyperglycemia)<sup>1</sup>**

<sup>\*</sup>The two most common side effects — dizziness and fatigue — occurred at rates comparable to placebo.

<sup>††</sup>Clinical trial response rates were: 2.5 mg—61%; 5 mg—73%; 10 mg—80%.

ZIAC is contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS section of full Prescribing Information), second- or third-degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

Please see Brief Summary of Prescribing Information on adjacent page.

First-line therapy option

**ZIAC<sup>™</sup>**

(bisoprolol fumarate-hydrochlorothiazide)  
2.5, 5, & 10 mg Tablets with 6.25 mg HCTZ

First-line therapy option  
**ZIAC™**  
 (bisoprolol fumarate-hydrochlorothiazide)  
 2.5, 5, & 10 mg Tablets with 6.25 mg HCTZ

**References:**

- DeQuattro V, Weir MR. Bisoprolol fumarate/hydrochlorothiazide 6.25 mg: a new, low-dose option for first-line antihypertensive therapy. *Adv Ther.* 1993;10:197-206.
- Lewin AJ, Lueg MC, Targum S, et al. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. *Clin Cardiol.* 1993;16:732-736.

**Brief Summary**

**ZIAC™ (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets**

FOR FULL PRESCRIBING INFORMATION, PLEASE CONSULT PACKAGE INSERT.

**DESCRIPTION**

ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated for the treatment of hypertension. It combines two antihypertensive agents in a once-daily dosage: a synthetic beta<sub>1</sub>-selective (cardioselective) adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide).

**CLINICAL PHARMACOLOGY**

At doses  $\geq$  20 mg bisoprolol fumarate inhibits beta<sub>1</sub>-adrenoreceptors located in bronchial and vascular musculature. To retain relative selectivity, it is important to use the lowest effective dose.

**CONTRAINDICATIONS**

Cardiogenic shock, overt cardiac failure (see **WARNINGS**), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

**WARNINGS**

**Cardiac Failure:** Beta-blocking agents should be avoided in patients with overt congestive failure.  
**Patients Without a History of Cardiac Failure:** Continued depression of the myocardium with beta-blockers can precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of ZIAC should be considered.

**Abrupt Cessation of Therapy:** Abrupt cessation of beta-blockers should be avoided. Even in patients without overt coronary artery disease, it may be advisable to taper therapy with ZIAC over approximately 1 week with the patient under careful observation. If withdrawal symptoms occur, beta-blocking agent therapy should be reinstated, at least temporarily.

**Peripheral Vascular Disease:** Beta-blockers should be used with caution in patients with peripheral vascular disease.

**Bronchospastic Disease:** PATIENTS WITH BRONCHOSPASTIC PULMONARY DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS.

**Anesthesia and Major Surgery:** If used perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used.

**Diabetes and Hypoglycemia:** Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned. Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose.

**Thyroid Disease:** Beta-adrenergic blockade may mask clinical signs of hyperthyroidism. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm.

**Renal Disease:** Cumulative effects of the thiazides may develop in patients with impaired renal function. In such patients, thiazides may precipitate azotemia. In subjects with creatinine clearance less than 40 mL/min, the plasma half-life of bisoprolol fumarate is increased up to threefold, as compared to healthy subjects.

**Hepatic Disease:** ZIAC should be used with caution in patients with impaired hepatic function or progressive liver disease.

**PRECAUTIONS**

**General: Electrolyte and Fluid Balance Status:** Periodic determination of serum electrolytes should be performed, and patients should be observed for signs of fluid or electrolyte disturbances. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hypokalemia may develop. Hypokalemia and hypomagnesemia can provoke ventricular arrhythmias or sensitize or exaggerate the response of the heart to the toxic effects of digitalis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than salt administration, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

**Parathyroid Disease:** Calcium excretion is decreased by thiazides, and pathologic changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have been observed in a few patients on prolonged thiazide therapy. **Hyperuricemia:** Hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics. Bisoprolol fumarate, alone or in combination with HCTZ, has been associated with increases in uric acid.

**Drug Interactions:** ZIAC may potentiate the action of other antihypertensive agents used concomitantly. ZIAC should not be combined with other beta-blocking agents. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZIAC be discontinued for several days before the withdrawal of clonidine.

ZIAC should be used with caution when myocardial depressants or inhibitors of AV conduction or anti-arrhythmic agents are used concurrently.

**Bisoprolol Fumarate:** Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, dipoxin and cimetidine. There was no effect of bisoprolol fumarate on prothrombin times in patients on stable doses of warfarin.

While taking beta-blockers, patients with a history of severe anaphylactic reaction may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.

**Hydrochlorothiazide:** The following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics—potentiation of orthostatic hypotension may occur. Dosage adjustment of the antidiabetic drugs (oral agents and insulin) may be required. Other antihypertensive drugs—additive effect or potentiation. Cholestyramine and colestipol resins—single doses of cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption in the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH—intensified electrolyte depletion, particularly hypokalemia. Possible decreased response to pressor amines but not sufficient to preclude their use. Possible increased responsiveness to muscle relaxants, nondopaminergic. Generally, lithium should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. The administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.

In patients receiving thiazides, sensitivity reactions may occur with or without a history of allergy or bronchial asthma. Photosensitivity reactions and possible exacerbation or activation of systemic lupus erythematosus have been reported in patients receiving thiazides. The antihypertensive effects of thiazides may be enhanced in the post-sympathectomy patient.

**Laboratory Test Interactions:** Based on reports involving thiazides, ZIAC may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. Because it includes a thiazide, ZIAC should be discontinued before carrying out tests for parathyroid function (see **PRECAUTIONS—Parathyroid Disease**).

**ADVERSE REACTIONS**

ZIAC: Bisoprolol fumarate/H<sub>2</sub>O.25 mg is well tolerated in most patients. Most adverse effects (AEs) have been mild and transient. In more than 65,000 patients treated worldwide with bisoprolol fumarate, occurrences of bronchospasm have been rare. Discontinuation rates for AEs were similar for B/H<sub>2</sub>O.25 mg and placebo-treated patients.

In the United States, 252 patients received bisoprolol fumarate (2.5, 5, 10, or 40 mg)/H<sub>2</sub>O.25 mg and 144 patients received placebo in two controlled trials. In Study 1, bisoprolol fumarate 5/H<sub>2</sub>O.25 mg was administered for 4 weeks. In Study 2, bisoprolol fumarate 2.5, 10 or 40/H<sub>2</sub>O.25 mg was administered for 12 weeks. All adverse experiences, whether drug-related or not, and drug-related adverse experiences in patients treated with B2.5-10/H<sub>2</sub>O.25 mg, reported during comparable, 4 week treatment periods by at least 2% of bisoprolol fumarate/H<sub>2</sub>O.25 mg-treated patients (plus additional selected adverse experiences) are presented in the following table:

**ZIAC™ (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets**

Body System/ Adverse Experience	% of Patients with Adverse Experiences*			
	All Adverse Experiences		Drug-related Adverse Experiences	
	Placebo† (n = 144) %	B2.5-10/H <sub>2</sub> O.25† (n = 252) %	Placebo† (n = 144) %	B2.5-10/H <sub>2</sub> O.25† (n = 221) %
Cardiovascular				
bradycardia	0.7	1.1	0.7	0.9
arrhythmia	1.4	0.4	0.0	0.0
peripheral ischemia	0.9	0.7	0.9	0.4
chest pain	0.7	1.8	0.7	0.9
Respiratory				
bronchospasm	0.0	0.0	0.0	0.0
cough	1.0	2.2	0.7	1.5
rhinitis	2.0	0.7	0.7	0.9
URI	2.3	2.1	0.0	0.0
Body as a Whole				
asthenia	0.0	0.0	0.0	0.0
fatigue	2.7	4.6	1.7	3.0
peripheral edema	0.7	1.1	0.7	0.9
Central Nervous System				
dizziness	1.8	5.1	1.8	3.2
headache	4.7	4.5	2.7	0.4
Musculoskeletal				
muscle cramps	0.7	1.2	0.7	1.1
myalgia	1.4	2.4	0.0	0.0
Psychiatric				
insomnia	2.4	1.1	2.0	1.2
somnia	0.7	1.1	0.7	0.9
loss of libido	1.2	0.4	1.2	0.4
impotence	0.7	1.1	0.7	1.1
Gastrointestinal				
diarrhea	1.4	4.3	1.2	1.1
nausea	0.9	1.1	0.9	0.9
dyspepsia	0.7	1.2	0.7	0.9

\*Averages adjusted to combine across studies.

† Combined across studies.

Other adverse experiences that have been reported with the individual components are listed below.  
**Bisoprolol Fumarate:** In clinical trials worldwide, a variety of other AEs, in addition to those listed above, have been reported. While in many cases it is not known whether a causal relationship exists between bisoprolol and these AEs, they are listed to alert the physician to a possible relationship. **Central Nervous System:** Inattention, dizziness, vertigo, syncope, paresthesia, hyperesthesia, sleep disturbance/vivid dreams, depression, anxiety/restlessness, decreased concentration/memory. **Cardiovascular:** Palpitations and other rhythm disturbances, cold extremities, claudication, hypertension, orthostatic hypotension, chest pain, congestive heart failure. **Gastrointestinal:** Gastric/epigastric/abdominal pain, peptic ulcer, gastritis, vomiting, constipation, dry mouth. **Musculoskeletal:** Arthralgia, muscle/joint pain, back/neck pain, twitching/tremor. **Skin:** Rash, acne, eczema, psoriasis, skin irritation, pruritus, purpura, flushing, sweating, alopecia, dermatitis, exfoliative dermatitis (very rarely). **Special Senses:** Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing, earache, taste abnormalities. **Metabolic:** Gout. **Respiratory:** Asthma, bronchitis, dyspnea, pharyngitis, sinusitis. **Genitourinary:** Peyronie's disease (very rarely), cystitis, renal colic, polyuria. **General:** Malaise, edema, weight gain, angioedema.

In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects: **Central Nervous System:** Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium. **Allergic:** Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. **Hematologic:** Agranulocytosis, thrombocytopenia. **Gastrointestinal:** Mesenteric arterial thrombosis and ischemic colitis. **Miscellaneous:** The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate during investigational use or extensive foreign marketing experience.

**Hydrochlorothiazide:** The following adverse experiences, in addition to those listed in the above table, have been reported with hydrochlorothiazide (generally with doses of 25 mg or greater). **General:** Weakness. **Central Nervous System:** Vertigo, paresthesia, restlessness. **Cardiovascular:** Orthostatic hypotension (may be potentiated by alcohol, barbiturates, or narcotics). **Gastrointestinal:** Anorexia, gastric irritation, cramping, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, cholecystitis, sialadenitis, dry mouth. **Musculoskeletal:** Muscle spasm. **Hypersensitive Reactions:** Purpura, photosensitivity, rash, urticaria, necrotizing angitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions. **Special Senses:** Transient blurred vision, xanthopsia. **Metabolic:** Gout. **Genitourinary:** Sexual dysfunction, renal failure, renal dysfunction, interstitial nephritis.

**LABORATORY ABNORMALITIES**

ZIAC: Because of the low dose of hydrochlorothiazide in ZIAC, adverse metabolic effects with B/H<sub>2</sub>O.25 mg are less frequent and of smaller magnitude than with HCTZ 25 mg.

Treatment with both beta-blockers and thiazide diuretics is associated with increases in uric acid. Mean increases in serum triglycerides were observed in patients treated with bisoprolol fumarate and hydrochlorothiazide 6.25 mg. Total cholesterol was generally unaffected, but small decreases in HDL cholesterol were noted.

Other laboratory abnormalities that have been reported with the individual components are listed below.  
**Bisoprolol Fumarate:** In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding.

Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4 to 12 weeks, the incidence of concomitant elevations in SGOT and SGPT of between 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal.

In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in SGOT and SGPT of between 1-2 times normal was 6.2%. The incidence of multiple occurrence was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate.

Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. There have been occasional reports of eosinophilia. These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate.

As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.


**Hydrochlorothiazide:** Hyperglycemia, glycosuria, hyperuricemia, hypokalemia and other electrolyte imbalances (see **PRECAUTIONS**), hyperlipidemia, hypercalcemia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia have been associated with HCTZ therapy.

See **DOSE AND ADMINISTRATION** section in package insert for complete dosing and precautionary information.

 ADVANTUS PHARMACEUTICALS and  
 LEDERLE LABORATORIES DIVISION  
 American Cyanamid Company  
 Pearl River, NY 10965

Under license of E. MERCK, Darmstadt, Germany

REV. 3/93  
 L-32073-93

 LEDERLE LABORATORIES  
 A Division of American Cyanamid Company  
 Wayne, New Jersey 07470

Under license of E. MERCK, Darmstadt, Germany

Copromoted by  
 **Procter & Gamble**  
 PHARMACEUTICALS

# ATTENTION

## DIPLOMATES OF THE ABFP ADDRESS CHANGE FORM

***** 3-DIGIT-080 0028 (12345) 76/88 ABFP BEVERLY J. CLARK MD 24 LEXINGTON ST AKRON OH 44309
--

5-digit ABFP Identification Number

The Board prefers the use of *professional addresses*, because the address given will become your "address of record" with the Board and will be published in our Directory of Diplomates.

Current addresses for all Diplomates are necessary for communication from the Board relating to the Examinations, up-dated Recertification information, etc., as well as to ensure the receipt of *The Journal of the American Board of Family Practice*.

Name \_\_\_\_\_

### Current Address

### New Address

Street \_\_\_\_\_

Street \_\_\_\_\_

City/State \_\_\_\_\_

City/State \_\_\_\_\_

Zip Code \_\_\_\_\_

Zip Code \_\_\_\_\_

Effective Date of Change \_\_\_\_\_

Signature of Diplomate \_\_\_\_\_

ABFP Identification Number \_\_\_\_\_  
(5-digit number above name on mailing label)

Year of Certification or Recertification \_\_\_\_\_

**Return to:**

**Ann Stockham  
The American Board of Family Practice  
2228 Young Drive  
Lexington, KY 40505**



**Added  
Power...**

**Without  
Added  
Problems**

- LORCET® 10/650 is stronger than any other hydrocodone tablet available.
- LORCET® 10/650 is well tolerated—nausea, vomiting, sedation, and constipation have seldom been reported.<sup>1</sup>
- LORCET® 10/650 offers class III prescribing convenience—it can be prescribed by phone,\* with up to five refills in 6 months, and requires no triplicates.

**Lorcet® 10/650** 

Each tablet contains: 10 mg hydrocodone bitartrate (**Warning: May be habit-forming**) and 650 mg acetaminophen.

Call **1-800-821-8460**  
for free samples and  
product information.

**The Phone-In Pain Relief with the Most Power**

\* In most states.

*For reference and brief summary of prescribing information, see adjacent page.*

© 1994 Forest Laboratories, Inc.

Printed in USA

April 1994

L10-26A

# Lorcet<sup>®</sup> 10/650

Each tablet contains: 10 mg hydrocodone bitartrate (**Warning: May be habit-forming**) and 650 mg acetaminophen.

#### Reference:

1. Data on file, Forest Laboratories, New York, NY.

#### BRIEF SUMMARY

**INDICATIONS AND USAGE:** For the relief of moderate to moderately severe pain.  
**CONTRAINDICATIONS:** Hypersensitivity to acetaminophen or hydrocodone.  
**WARNINGS: Respiratory Depression:** At high doses or in sensitive patients, hydrocodone may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.  
**Head Injury and Increased Intracranial Pressure:** The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.  
**Acute Abdominal Conditions:** The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.  
**PRECAUTIONS: Special Risk Patients:** As with any narcotic analgesic agent, Lorcet<sup>®</sup> 10/650 should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.  
**Cough Reflex:** Hydrocodone suppresses the cough reflex; as with all narcotics, caution should be exercised when Lorcet<sup>®</sup> 10/650 is used postoperatively and in patients with pulmonary disease.  
**Drug Interactions:** Patients receiving other narcotic analgesics, antipsychotics, antiemetic agents, or other CNS depressants (including alcohol) concomitantly with Lorcet<sup>®</sup> 10/650 may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced. The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone. The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.  
**Use in Pregnancy: Teratogenic Effects:** Pregnancy Category C. Hydrocodone has been shown to be teratogenic in hamsters when given in doses 700 times the human dose. There are no adequate and well-controlled studies in pregnant women. Lorcet<sup>®</sup> 10/650 should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
**Nonteratogenic Effects:** Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Chlorpromazine 0.7 to 1 mg/kg q6h, and paregoric 2 to 4 drops/kg q4h, have been used to treat withdrawal symptoms in infants. The duration of therapy is 4 to 28 days, with the dosage decreased as tolerated.  
**Labor and Delivery:** As with all narcotics, administration of Lorcet<sup>®</sup> 10/650 to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.  
**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Lorcet<sup>®</sup> 10/650, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  
**Pediatric Use:** Safety and effectiveness in children have not been established.  
**ADVERSE REACTIONS:** The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include:  
**Central Nervous System:** Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychic dependence, mood changes.  
**Gastrointestinal System:** The antiemetic phenothiazines are useful in suppressing the nausea and vomiting which may occur (see above); however, some phenothiazine derivatives seem to be antianalgesic and to increase the amount of narcotic required to produce pain relief, while other phenothiazines reduce the amount of narcotic required to produce a given level of analgesia. Prolonged administration of Lorcet<sup>®</sup> 10/650 may produce constipation.  
**Genitourinary System:** Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported.  
**Respiratory Depression:** Hydrocodone bitartrate may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing. If significant respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride. Apply other supportive measures when indicated.  
**DRUG ABUSE AND DEPENDENCE:** Lorcet<sup>®</sup> 10/650 is subject to the Federal Controlled Substances Act (Schedule III). Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, Lorcet<sup>®</sup> 10/650 should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when Lorcet<sup>®</sup> 10/650 is used for a short time for the treatment of pain.  
**OVERDOSAGE: Acetaminophen: Signs and Symptoms:** In acute acetaminophen overdosage, dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post ingestion.  
**Hydrocodone: Signs and Symptoms:** Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.  
**DOSAGE AND ADMINISTRATION:** Dosage should be adjusted according to the severity of the pain and the response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related. The usual adult dosage is one tablet every four to six hours as needed for pain. The total 24 hour dose should not exceed 6 tablets.  
**CAUTION:** Federal law prohibits dispensing without prescription. A Schedule III Controlled Substance. Manufactured by: MIKART, INC., ATLANTA, GA 30318. Manufactured for: UAD Laboratories Division of Forest Pharmaceuticals, Inc., Jackson, MS 39209 Rev. 11/92 Code 558A00




UAD LABORATORIES  
Division of Forest Pharmaceuticals, Inc.  
Jackson, Mississippi 39209-9658



FOREST PHARMACEUTICALS, INC.  
A subsidiary of Forest Laboratories, Inc.  
St. Louis, Missouri 63045

# MEDICAL USES OF STATISTICS

## SECOND EDITION



J. C. Bailar III, M.D., Ph.D.  
and F. Mosteller, Ph.D.

## A Practical Approach to Statistics

If you've been looking for an overview of medical statistics that's understandable, easy to apply, and up-to-date, order your own copy today!

Contents: Revised & Updated

— Plus 7 New Chapters

©1992, 490 pages, 90 illus., paperback.

ISBN 0-910133-36-0



## The New England Journal of Medicine

**YES!** send me a copy of the Second Edition of *Medical Uses of Statistics* at \$39.95, plus \$3.50 postage and handling\*.

Check is enclosed for \$ \_\_\_\_\_  
 Charge my  VISA  MasterCard  AmEx

CARD NO. \_\_\_\_\_ EXP. DATE \_\_\_\_\_

SIGNATURE \_\_\_\_\_

NAME/SPECIALTY \_\_\_\_\_  
(PLEASE PRINT)

ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_

STATE \_\_\_\_\_ ZIP \_\_\_\_\_

Send to: **NEJM BOOKS**

The New England Journal of Medicine  
P.O. Box 9130, Waltham, MA 02254-9130  
Toll Free 1-800-THE-NEJM  
FAX: 617-893-0413

\*Make check payable to the *New England Journal of Medicine*. MA residents add 5% sales tax. SATISFACTION GUARANTEED or full refund within 30 days.

Allow 4-6 weeks for delivery.

SDS2

